172 related articles for article (PubMed ID: 20735381)
21. Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder.
Staack A; Badendieck S; Schnorr D; Loening SA; Jung K
BMC Urol; 2006 Aug; 6():19. PubMed ID: 16901349
[TBL] [Abstract][Full Text] [Related]
22. Risk factors for local recurrence in patients with pTa/pT1 urinary bladder cancer.
Jancke G; Damm O; Rosell J; Jahnson S
Scand J Urol Nephrol; 2008; 42(5):417-21. PubMed ID: 18609266
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma.
Mizutani Y; Matsubara H; Yamamoto K; Nan Li Y; Mikami K; Okihara K; Kawauchi A; Bonavida B; Miki T
Cancer; 2004 Oct; 101(8):1794-802. PubMed ID: 15386310
[TBL] [Abstract][Full Text] [Related]
24. Immunomagnetic quantification of circulating tumoral cells in patients with prostate cancer: clinical and pathological correlation.
Resel Folkersma L; Olivier Gómez C; San José Manso L; Veganzones de Castro S; Galante Romo I; Vidaurreta Lázaro M; de la Orden GV; Arroyo Fernández M; Díaz Rubio E; Silmi Moyano A; Maestro de Las Casas MA
Arch Esp Urol; 2010; 63(1):23-31. PubMed ID: 20157216
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of circulating tumour cells enumerated after filtration enrichment in early and metastatic breast cancer patients.
Wong NS; Kahn HJ; Zhang L; Oldfield S; Yang LY; Marks A; Trudeau ME
Breast Cancer Res Treat; 2006 Sep; 99(1):63-9. PubMed ID: 16541316
[TBL] [Abstract][Full Text] [Related]
26. Blood group H antigen in transitional carcinoma of the urinary bladder.
Tichý M; Tichá V; Jansa P; Student V; Vanák J
Acta Univ Palacki Olomuc Fac Med; 1991; 130():157-62. PubMed ID: 1838863
[TBL] [Abstract][Full Text] [Related]
27. [Skin metastasis from invasive bladder tumour].
Haouas N; Youssef A; Sahraoui W; Thabet I; Ben Sorba N; Jaidane M; Haddad N; Mosbah AT
Prog Urol; 2005 Jun; 15(3):535-7. PubMed ID: 16097168
[TBL] [Abstract][Full Text] [Related]
28. CA19.9 and CEA in transitional cell carcinoma of the bladder: serological and immunohistochemical findings.
Hegele A; Mecklenburg V; Varga Z; Olbert P; Hofmann R; Barth P
Anticancer Res; 2010 Dec; 30(12):5195-200. PubMed ID: 21187512
[TBL] [Abstract][Full Text] [Related]
29. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis.
Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
Hum Pathol; 2006 Dec; 37(12):1568-76. PubMed ID: 16949911
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of survivin-expressing circulating tumour cells in T1G3 bladder cancer.
Gradilone A; Petracca A; Nicolazzo C; Gianni W; Cortesi E; Naso G; Vincenzi B; Cristini C; De Berardinis E; Di Silverio F; Aglianò AM; Gazzaniga P
BJU Int; 2010 Sep; 106(5):710-5. PubMed ID: 20128783
[TBL] [Abstract][Full Text] [Related]
31. Molecular genetic methods in the diagnosis of invasive bladder cancer.
Krause FS; Feil G; Zumbrägel A; Bichler KH
Anticancer Res; 2000; 20(6D):5015-21. PubMed ID: 11326660
[TBL] [Abstract][Full Text] [Related]
32. Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer.
Andrews B; Shariat SF; Kim JH; Wheeler TM; Slawin KM; Lerner SP
J Urol; 2002 Mar; 167(3):1475-81. PubMed ID: 11832773
[TBL] [Abstract][Full Text] [Related]
33. Molecular detection of telomerase-positive circulating epithelial cells in metastatic breast cancer patients.
Soria JC; Gauthier LR; Raymond E; Granotier C; Morat L; Armand JP; Boussin FD; Sabatier L
Clin Cancer Res; 1999 May; 5(5):971-5. PubMed ID: 10353728
[TBL] [Abstract][Full Text] [Related]
34. Clinical use of serum CA-125 levels in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.
Kouba EJ; Lentz A; Wallen EM; Pruthi RS
Urol Oncol; 2009; 27(5):486-90. PubMed ID: 18555706
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of circulating cytotoxic lymphocytes against autologous tumors in patients with bladder cancer.
Mizutani Y; Okada Y; Terachi T; Yoshida O
J Urol; 1996 Mar; 155(3):888-92; discussion 892-4. PubMed ID: 8583600
[TBL] [Abstract][Full Text] [Related]
36. Bladder carcinoma: understanding advanced and metastatic disease with potential molecular therapeutic targets.
Ahmed HU; Arya M; Patel HR
Expert Rev Anticancer Ther; 2005 Dec; 5(6):1011-22. PubMed ID: 16336092
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: a CellSearch analysis.
Gazzaniga P; Gradilone A; de Berardinis E; Busetto GM; Raimondi C; Gandini O; Nicolazzo C; Petracca A; Vincenzi B; Farcomeni A; Gentile V; Cortesi E; Frati L
Ann Oncol; 2012 Sep; 23(9):2352-2356. PubMed ID: 22351740
[TBL] [Abstract][Full Text] [Related]
38. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
39. M30 neoepitope expression in epithelial cancer: quantification of apoptosis in circulating tumor cells by CellSearch analysis.
Rossi E; Basso U; Celadin R; Zilio F; Pucciarelli S; Aieta M; Barile C; Sava T; Bonciarelli G; Tumolo S; Ghiotto C; Magro C; Jirillo A; Indraccolo S; Amadori A; Zamarchi R
Clin Cancer Res; 2010 Nov; 16(21):5233-43. PubMed ID: 20978147
[TBL] [Abstract][Full Text] [Related]
40. Urinary fibronectin as a predictor of a residual tumour load after transurethral resection of bladder transitional cell carcinoma.
Li LY; Yang M; Zhang HB; Su XK; Xu WF; Chen Y; Shen ZJ; Gao X
BJU Int; 2008 Aug; 102(5):566-71. PubMed ID: 18410436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
